Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd.

A. Von Seefried, J. H. Chun, J. A. Grant, L. Letvenuk, E. W. Pearson

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Trivalent inactivated poliovirus vaccine (IPV) (MK) was made, purified, and inactivated according to the amended Rijks Instituut (The Netherlands) protocol from primary monkey kidney tissue grown on microcarrier cultures. Losses of the type 2 component due to adsorption to the glass ampule occurred with the purified vaccine preparation. This problem was solved by changing the diluent, and the vaccine was submitted for evaluation in clinical trials at Johns Hopkins (Baltimore, Md.). Phase 2 of the development was to standardize production of IPV from MRC-5 (human diploid) cells on microcarriers and otherwise follow the Rijks Instituut 's method. Results of experimental trivalent vaccine production and testing showed that the number of effective doses harvested from MRC-5 cell cultures compared favorably with vaccine derived from monkey kidney. The yields could be further increased with stearyl tyrosine as adjuvant. Large-scale production using 200-liter fermenters is in progress. Poliovirus particles of various densities in cesium chloride can be found in any IPV preparation and give rise to different immunogenic responses. As shown in this paper, some of these virus fractions produce a low primary humoral antibody response but appear to be important for memory induction.

Original languageEnglish (US)
JournalReviews of Infectious Diseases
Volume6 Suppl 2
StatePublished - May 1984

Fingerprint

Inactivated Poliovirus Vaccine
Vaccines
Haplorhini
Kidney
Baltimore
Poliovirus
Diploidy
Netherlands
Adsorption
Antibody Formation
Glass
Cell Culture Techniques
Clinical Trials
Viruses

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Von Seefried, A., Chun, J. H., Grant, J. A., Letvenuk, L., & Pearson, E. W. (1984). Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd. Reviews of Infectious Diseases, 6 Suppl 2.

Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd. / Von Seefried, A.; Chun, J. H.; Grant, J. A.; Letvenuk, L.; Pearson, E. W.

In: Reviews of Infectious Diseases, Vol. 6 Suppl 2, 05.1984.

Research output: Contribution to journalArticle

Von Seefried, A, Chun, JH, Grant, JA, Letvenuk, L & Pearson, EW 1984, 'Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd.', Reviews of Infectious Diseases, vol. 6 Suppl 2.
Von Seefried A, Chun JH, Grant JA, Letvenuk L, Pearson EW. Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd. Reviews of Infectious Diseases. 1984 May;6 Suppl 2.
Von Seefried, A. ; Chun, J. H. ; Grant, J. A. ; Letvenuk, L. ; Pearson, E. W. / Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd. In: Reviews of Infectious Diseases. 1984 ; Vol. 6 Suppl 2.
@article{b732e6f5a7264b1c9d13371bb2001f8c,
title = "Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd.",
abstract = "Trivalent inactivated poliovirus vaccine (IPV) (MK) was made, purified, and inactivated according to the amended Rijks Instituut (The Netherlands) protocol from primary monkey kidney tissue grown on microcarrier cultures. Losses of the type 2 component due to adsorption to the glass ampule occurred with the purified vaccine preparation. This problem was solved by changing the diluent, and the vaccine was submitted for evaluation in clinical trials at Johns Hopkins (Baltimore, Md.). Phase 2 of the development was to standardize production of IPV from MRC-5 (human diploid) cells on microcarriers and otherwise follow the Rijks Instituut 's method. Results of experimental trivalent vaccine production and testing showed that the number of effective doses harvested from MRC-5 cell cultures compared favorably with vaccine derived from monkey kidney. The yields could be further increased with stearyl tyrosine as adjuvant. Large-scale production using 200-liter fermenters is in progress. Poliovirus particles of various densities in cesium chloride can be found in any IPV preparation and give rise to different immunogenic responses. As shown in this paper, some of these virus fractions produce a low primary humoral antibody response but appear to be important for memory induction.",
author = "{Von Seefried}, A. and Chun, {J. H.} and Grant, {J. A.} and L. Letvenuk and Pearson, {E. W.}",
year = "1984",
month = "5",
language = "English (US)",
volume = "6 Suppl 2",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd.

AU - Von Seefried, A.

AU - Chun, J. H.

AU - Grant, J. A.

AU - Letvenuk, L.

AU - Pearson, E. W.

PY - 1984/5

Y1 - 1984/5

N2 - Trivalent inactivated poliovirus vaccine (IPV) (MK) was made, purified, and inactivated according to the amended Rijks Instituut (The Netherlands) protocol from primary monkey kidney tissue grown on microcarrier cultures. Losses of the type 2 component due to adsorption to the glass ampule occurred with the purified vaccine preparation. This problem was solved by changing the diluent, and the vaccine was submitted for evaluation in clinical trials at Johns Hopkins (Baltimore, Md.). Phase 2 of the development was to standardize production of IPV from MRC-5 (human diploid) cells on microcarriers and otherwise follow the Rijks Instituut 's method. Results of experimental trivalent vaccine production and testing showed that the number of effective doses harvested from MRC-5 cell cultures compared favorably with vaccine derived from monkey kidney. The yields could be further increased with stearyl tyrosine as adjuvant. Large-scale production using 200-liter fermenters is in progress. Poliovirus particles of various densities in cesium chloride can be found in any IPV preparation and give rise to different immunogenic responses. As shown in this paper, some of these virus fractions produce a low primary humoral antibody response but appear to be important for memory induction.

AB - Trivalent inactivated poliovirus vaccine (IPV) (MK) was made, purified, and inactivated according to the amended Rijks Instituut (The Netherlands) protocol from primary monkey kidney tissue grown on microcarrier cultures. Losses of the type 2 component due to adsorption to the glass ampule occurred with the purified vaccine preparation. This problem was solved by changing the diluent, and the vaccine was submitted for evaluation in clinical trials at Johns Hopkins (Baltimore, Md.). Phase 2 of the development was to standardize production of IPV from MRC-5 (human diploid) cells on microcarriers and otherwise follow the Rijks Instituut 's method. Results of experimental trivalent vaccine production and testing showed that the number of effective doses harvested from MRC-5 cell cultures compared favorably with vaccine derived from monkey kidney. The yields could be further increased with stearyl tyrosine as adjuvant. Large-scale production using 200-liter fermenters is in progress. Poliovirus particles of various densities in cesium chloride can be found in any IPV preparation and give rise to different immunogenic responses. As shown in this paper, some of these virus fractions produce a low primary humoral antibody response but appear to be important for memory induction.

UR - http://www.scopus.com/inward/record.url?scp=0021435922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021435922&partnerID=8YFLogxK

M3 - Article

VL - 6 Suppl 2

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -